Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Serkan Oray from UCB shares why the autoinjector pen format is booming, the importance of a patient-centric design, and how ...

At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...

Biologics are incredibly powerful and targeted. For these reasons, pharmaceutical companies have invested a lot of time and money over the past 20 years developing medications based on these ...

Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients With Early Rheumatoid Arthritis (the Best Study): A Randomized, Controlled Trialfrom Arthritis & Rheumatism ...